Acute Respiratory Distress Syndrome Market by Type (Diagnostics, Treatment), Cause (Direct Lung Injury, Indirect Lung Injury), End-user - Global Forecast 2024-2030

Acute Respiratory Distress Syndrome Market by Type (Diagnostics, Treatment), Cause (Direct Lung Injury, Indirect Lung Injury), End-user - Global Forecast 2024-2030


The Acute Respiratory Distress Syndrome Market size was estimated at USD 2.56 billion in 2023 and expected to reach USD 2.72 billion in 2024, at a CAGR 6.13% to reach USD 3.89 billion by 2030.

Acute respiratory distress syndrome (ARDS) is a severe lung condition characterized by rapid onset of widespread inflammation in the lungs. ARDS is a type of respiratory failure that occurs when fluid is produced in the tiny, elastic air sacs (alveoli) in the lungs. The fluid controls the lungs from filling with sufficient air, which means less oxygen reaches the bloodstream. Products and services in the ARDS market are applied in critical care settings, including intensive care units (ICUs) in hospitals and emergency departments, where patients with severe respiratory failure receive treatment. Several factors influence the growth of the ARDS market. The increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections, drives the demand for effective treatments. Technological advancements in mechanical ventilation and supportive therapies contribute to market growth. Additionally, the heightened focus on research and development of new pharmaceuticals and the expanding awareness and understanding of ARDS among healthcare providers propel the market forward. Despite growth prospects, the ARDS market faces challenges such as high treatment costs and limited accessibility to advanced care in low-income regions that restrict market expansion. Furthermore, the complexity of ARDS, variability in patient response to treatments, and a still-evolving understanding of its pathophysiology make developing universally effective treatments challenging. On the other hand, the development of personalized medicine approaches targeting the molecular and immunological underpinnings of ARDS presents a significant opportunity. Additionally, expanding markets in emerging economies, with increasing healthcare infrastructure investments, offer new avenues for growth. Collaboration between academic, research institutions, and industry in developing innovative therapies also opens up potential opportunities.

Regional Insights

The Americas, particularly the United States and Canada, have shown a significant need for advanced treatments for acute respiratory distress syndrome (ARDS). The high prevalence of ARDS in these regions, compounded by robust healthcare infrastructure, has facilitated substantial market growth. Customer purchasing behavior in the Americas tends to lean towards innovative, evidence-based treatments, reflecting a trust in advanced medical technology and pharmaceutical interventions. In South America, the market for ARDS treatments and diagnostics is gradually expanding, with Brazil and Argentina at the forefront, investing in healthcare infrastructure and clinical research. Europe represents a significant market for ARDS, with Western European countries are at forefront in terms of research, treatment adoption, and market revenues. The region benefits from strong healthcare systems and widespread adoption of advanced therapeutics. Moreover, numerous initiatives and collaborations aim to address ARDS, elevating the urgency for effective management strategies. In contrast, the Middle East and Africa face distinctive challenges, including limited access to healthcare services and a lack of specialized medical facilities in some areas. However, growing awareness and increasing healthcare expenditures are gradually improving the ARDS treatment landscape in these regions. The Asia-Pacific region is witnessing rapid market growth for ARDS treatments and diagnostics, fueled by rising healthcare spending and population growth. China, Japan, and India are conducting this growth due to their large populations and increasing prevalence of respiratory diseases. The region is also seeing a significant uptick in research initiatives and adoption of cutting-edge treatments. Government initiatives to improve healthcare systems are further propelling the market forward in the APAC region.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Acute Respiratory Distress Syndrome Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
  • Increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections
  • Advancements in mechanical ventilation and supportive therapies
  • Rising focus on research and development of new pharmaceuticals
Market Restraints
  • High treatment costs and limited accessibility to advanced care
Market Opportunities
  • Ongoing development of personalized medicine approaches
  • Increasing government initiatives and healthcare infrastructure investments
Market Challenges
  • Regulatory complexities for the approval of new therapies and devices
Market Segmentation Analysis
  • Type: Increasing need for diagnostics due to its potential for precision medicine application
  • End-user: Expanding preference for hospitals for management of ARDS
Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Acute Respiratory Distress Syndrome Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Acute Respiratory Distress Syndrome Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

BioAegis scores USD 20millon BARDA contract to develop ARDS therapy

BioAegis Therapeutics secured a USD 20 million contract from the US Biomedical Advanced Research and Development Authority (BARDA) for the treatment of Acute Respiratory Distress Syndrome (ARDS), under its DRIVe initiative, to advance the development of plasma gelsolin therapy.

Veru Inc., Reaches Agreement With FDA on a New Phase III Clinical Trial for Sabizabulin for Broader Indication Hospitalized Adult Patients with any Type of Viral Acute Respiratory Distress Syndrome ARDS

Veru Inc. announced the design of a new Phase III clinical trial study to evaluate sabizabulin plus standard of care treatment in an expanded patient population, hospitalized adult patients having any type of virus causing ARDS.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Acute Respiratory Distress Syndrome Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Acute Respiratory Distress Syndrome Market, highlighting leading vendors and their innovative profiles. These include APEPTICO GmbH, Armstrong Medical Ltd., Athersys, Inc., Bayer AG, Besmed Health Business Corp., Drägerwerk AG & Co. KGaA, EUROSETS S.R.L., F. Hoffmann-La Roche Ltd., Fisher & Paykel Healthcare Corporation Limited, GE HealthCare, Getinge AB, Hamilton Medical AG, HEALIOS K.K., LivaNova PLC, Novartis AG, NRx Pharmaceuticals, Pfizer Inc., Sun Pharmaceutical Industries Limited, Terumo Medical Corporation, United Therapeutics Corporation, and WEINMANN Emergency Medical Technology GmbH + Co. KG.

Market Segmentation & Coverage

This research report categorizes the Acute Respiratory Distress Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
  • Diagnostics
  • Treatment
  • Cause
  • Direct Lung Injury
  • Indirect Lung Injury
  • End-user
  • Hospital
  • Speciality Clinics
  • Region
  • Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas
  • Asia-Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam
  • Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom


Please Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections
5.1.1.2. Advancements in mechanical ventilation and supportive therapies
5.1.1.3. Rising focus on research and development of new pharmaceuticals
5.1.2. Restraints
5.1.2.1. High treatment costs and limited accessibility to advanced care
5.1.3. Opportunities
5.1.3.1. Ongoing development of personalized medicine approaches
5.1.3.2. Increasing government initiatives and healthcare infrastructure investments
5.1.4. Challenges
5.1.4.1. Regulatory complexities for the approval of new therapies and devices
5.2. Market Segmentation Analysis
5.2.1. Type: Increasing need for diagnostics due to its potential for precision medicine application
5.2.2. End-user: Expanding preference for hospitals for management of ARDS
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Acute Respiratory Distress Syndrome Market, by Type
6.1. Introduction
6.2. Diagnostics
6.3. Treatment
7. Acute Respiratory Distress Syndrome Market, by Cause
7.1. Introduction
7.2. Direct Lung Injury
7.3. Indirect Lung Injury
8. Acute Respiratory Distress Syndrome Market, by End-user
8.1. Introduction
8.2. Hospital
8.3. Speciality Clinics
9. Americas Acute Respiratory Distress Syndrome Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Acute Respiratory Distress Syndrome Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Acute Respiratory Distress Syndrome Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. BioAegis scores USD 20millon BARDA contract to develop ARDS therapy
12.3.2. Veru Inc., Reaches Agreement With FDA on a New Phase III Clinical Trial for Sabizabulin for Broader Indication Hospitalized Adult Patients with any Type of Viral Acute Respiratory Distress Syndrome ARDS
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings